A First in Human Phase 1 / 2 Multi-center Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of CTx001 Administered Via a Single Subretinal Injection in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Latest Information Update: 08 Mar 2026
At a glance
- Drugs CTx 001 Complement Therapeutics (Primary)
- Indications Dry age-related macular degeneration
- Focus Adverse reactions; First in man
- Acronyms Opti-GAIN
- Sponsors Complement Therapeutics
Most Recent Events
- 10 Feb 2026 New trial record